-1753360248087.webp&w=3840&q=75)
2025 NOSCM | Innovative Biomarkers and Potential New Pathways in Lung Cancer
0% Complete
Course Overview
Dr. Fred Hirsch discussed innovative targets and treatments in lung cancer, highlighting HER3, EGFR, SDK11, and KRAS mutations.
Course Content
Credits
- AMA PRA Category 1 Credit™Non-CME
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Fred Hirsch, MD, PhD, FASCO
Accreditation
NA
